Last reviewed · How we verify
IBI3032
At a glance
| Generic name | IBI3032 |
|---|---|
| Sponsor | Innovent Biologics Technology Limited (Shanghai R&D Center) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity (PHASE1)
- A Study of IBI3032 in Chinese Participants With Overweight or Obesity (PHASE1)
- A Study of IBI3032 in Chinese Healthy Subjects (EARLY_PHASE1)
- A Study of IBI3032 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI3032 CI brief — competitive landscape report
- IBI3032 updates RSS · CI watch RSS
- Innovent Biologics Technology Limited (Shanghai R&D Center) portfolio CI